Climate Change Data

Ascentage Pharma Group International (Incorporated in the Cayman Islands with limited liability)

Climate Impact & Sustainability Data (2019)

Reporting Period: 2019

Environmental Metrics

Total Carbon Emissions:907.28 ton of CO2 equivalent
Scope 2 Emissions:900.91 ton of CO2 equivalent
Total Energy Consumption:1,282,133.47 kWh
Water Consumption:4,360.80 m3
Waste Generated:4,360.80 tons

ESG Focus Areas

  • Environmental responsibility
  • Labor responsibility
  • Operational responsibility
  • Corporate governance responsibility

Environmental Achievements

  • Reduced emissions of pollutants to atmosphere, soil and waters by constantly improving process and implementing management and operation responsibility system
  • Implemented waste management system to regulate the management of waste collection, classification, storage, transfer and disposal

Social Achievements

  • Staff retention rate exceeded 90%
  • Donated RMB500,000 to Wuhan Union Hospital and Wuhan Tongji Hospital for purchasing urgently needed medical supplies to combat the epidemic
  • Organized procurement of supplies, spending a total amount of RMB500,000 to purchase urgently needed medical supplies from the United States, which were delivered to various hospitals in Wuhan
  • Encouraged all employees to make voluntary donations to purchase and donate 400 medical disposable protective clothing to Peking University People’s Hospital

Governance Achievements

  • Successfully listed on the Stock Exchange
  • Implemented comprehensive risk management policies at the business operation level to systematically manage various ESG risks
  • Established an Anti-Corruption Policy to safeguard against corruption; set up an internal reporting channel that is open and available for employees to report any suspected non-compliance

Climate Goals & Targets

Environmental Challenges

  • Potential safety hazards during the production or quality inspection of drugs
  • Potential safety hazards discovered in the complaint management procedures
  • Notices on defects from material suppliers
  • Regulatory authorities’ requirements on drug recalls and inquiries of drug quality by other authoritative institutions
Mitigation Strategies
  • Formulated and implemented a series of policies to ensure the safety of clinical trials
  • Strictly monitor the possibility for adverse events or quality issues, and follow up and adjust the trials in a timely manner
  • Established procedures for receiving and handling complaints in relation to drugs in clinical trials
  • Initiate the drug recall procedures and promptly recall products in accordance with the Clinical Trial Drug Recall Procedures

Supply Chain Management

Supplier Audits: approximately 300 suppliers

Responsible Procurement
  • Procurement and Supply Management Regulations
  • GMP Materials Procurement Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: ESG Guide as contained in Appendix 27 to The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited

Awards & Recognition

  • Innovative Team in Jiangsu Province
  • The Most Innovative Pharmaceutical Enterprise in the Asia-Pacific Region
  • Suzhou Biomedical Industrial Park EHS Best Practice Enterprise
  • Celebrating 70th Birthday of the Country and Building a New Era of Prosperity, Outstanding Enterprise in the Pharmaceutical Industry
  • New Wisdom Forum • 2019 Annual Value Pioneer Chart in Pharmaceutical Industry — Most Valuable Growing Enterprise in Pharmaceutical Industry